GlassScriptPhysician profile
Wesley Katherine Smith
NPI 1871186098
$4,013.38
in general payments reported to CMS, 2019-2025
25 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $848 · 2022: $2,248 · 2023: $725 · 2024: $37.40 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $1,109.54 | 2022-2023 | Intracept |
| Abbvie INC. | $489.74 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $367.03 | 2021-2023 | Relistor |
| Collegium Pharmaceutical, INC. | $335.68 | 2022-2023 | Xtampza |
| Teva Pharmaceuticals USA, INC. | $260.68 | 2021-2023 | Ajovy |
| Scilex Pharmaceuticals INC. | $180.15 | 2021-2023 | Ztlido |
| Upsher-Smith Laboratories LLC | $163.65 | 2021-2023 | |
| Abbott Laboratories | $159.85 | 2021 | |
| Jazz Pharmaceuticals INC. | $121.13 | 2025 | |
| Sk Life Science, INC. | $116.18 | 2023 | Xcopri |
| Boston Scientific Corporation | $83.43 | 2022-2025 | Wavewriter Alpha Prime 16, Intracept |
| Biohaven Pharmaceuticals, INC. | $80.35 | 2021 | |
| Protega Pharmaceutials INC | $70.89 | 2022-2023 | Roxybond |
| Lilly USA, LLC | $56.85 | 2021-2022 | |
| Fidia Pharma USA INC. | $52.28 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $47.62 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $45.88 | 2023 | Iovera, Zilretta |
| Allergan, INC. | $43.45 | 2021 | |
| Ibsa Pharma INC. | $41.87 | 2021 | |
| Nevro Corp. | $38.46 | 2021-2024 | Senza |
| Vertos Medical, INC. | $35.62 | 2022-2023 | Mild Device Kit |
| Biodelivery Sciences International, INC. | $35.51 | 2021 | |
| Bioventus LLC | $34.48 | 2021-2022 | |
| Amgen INC. | $24.08 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.98 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.